Skip to main content
PMC home page
Philosophical Transactions of the Royal Society B: Biological Sciences logoLink to Philosophical Transactions of the Royal Society B: Biological Sciences
. 2003 May 29;358(1433):955–960. doi: 10.1098/rstb.2003.1271

Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.

Chris Moyses 1
PMCID: PMC1693174  PMID: 12803929

Abstract

Glycosphingolipid (GSL) lysosomal storage disorders are inherited enzyme deficiencies that result in pathological lysosomal accumulation of glycolipids, with widespread clinical consequences. Type 1 Gaucher disease is the commonest of these; the deficient enzyme in this condition is glucocerebrosidase. Clinical manifestations include hepatosplenomegaly, thrombocytopenia, anaemia, recurrent infections and skeletal lesions. The condition can be treated with intravenous enzyme replacement therapy (ERT). Substrate reduction therapy is a new approach in which glycolipid accumulation is counteracted not by replacing the deficient enzyme but by reducing the substrate level to better balance residual activity of the deficient enzyme. Miglustat is an inhibitor of glucosylceramide synthase, a key enzyme in GSL synthesis. Oral administration of miglustat to patients with type 1 Gaucher disease attenuates the synthesis of glucocerebroside, the substrate of the deficient glucocerebrosidase. In the first clinical study, patients with type 1 Gaucher disease who had enlargement of the liver or spleen and (if present) the spleen at baseline received 12 months treatment with oral miglustat. There were mean decreases in liver and spleen volumes of 12% (7.9-16.4, p < 0.001) and 19% (14.3-23.7, p < 0.001), respectively. Mean haemoglobin increased by 0.26 g dl(-1) (-0.5-0.57, not statistically significant) and platelet count by 8.3 x 10(9) l(-1) (1.9-14.7, p = 0.014).

Full Text

The Full Text of this article is available as a PDF (195.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aerts J. M., Hollak C. E. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol. 1997 Dec;10(4):691–709. doi: 10.1016/s0950-3536(97)80034-0. [DOI] [PubMed] [Google Scholar]
  2. Aerts Johannes M., Hollak Carla, Boot Rolf, Groener Ans. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):905–914. doi: 10.1098/rstb.2003.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson N. L., Anderson N. G. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis. 1998 Aug;19(11):1853–1861. doi: 10.1002/elps.1150191103. [DOI] [PubMed] [Google Scholar]
  4. Barton N. W., Brady R. O., Dambrosia J. M., Di Bisceglie A. M., Doppelt S. H., Hill S. C., Mankin H. J., Murray G. J., Parker R. I., Argoff C. E. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991 May 23;324(21):1464–1470. doi: 10.1056/NEJM199105233242104. [DOI] [PubMed] [Google Scholar]
  5. Beutler E., Demina A., Laubscher K., Garver P., Gelbart T., Balicki D., Vaughan L. The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis. 1995;21(2):86–108. doi: 10.1006/bcmd.1995.0012. [DOI] [PubMed] [Google Scholar]
  6. Beutler E. Enzyme replacement therapy for Gaucher's disease. Baillieres Clin Haematol. 1997 Dec;10(4):751–763. doi: 10.1016/s0950-3536(97)80038-8. [DOI] [PubMed] [Google Scholar]
  7. Block T. M., Lu X., Platt F. M., Foster G. R., Gerlich W. H., Blumberg B. S., Dwek R. A. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2235–2239. doi: 10.1073/pnas.91.6.2235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brady R. O. Gaucher's disease: past, present and future. Baillieres Clin Haematol. 1997 Dec;10(4):621–634. doi: 10.1016/s0950-3536(97)80031-5. [DOI] [PubMed] [Google Scholar]
  9. Brady Roscoe O. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):915–919. doi: 10.1098/rstb.2003.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Butters Terry D., Mellor Howard R., Narita Keishi, Dwek Raymond A., Platt Frances M. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):927–945. doi: 10.1098/rstb.2003.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebícek M., Platt F., Butters T., Dwek R., Moyses C. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000 Apr 29;355(9214):1481–1485. doi: 10.1016/S0140-6736(00)02161-9. [DOI] [PubMed] [Google Scholar]
  12. Elstein D., Abrahamov A., Hadas-Halpern I., Meyer A., Zimran A. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM. 1998 Jul;91(7):483–488. doi: 10.1093/qjmed/91.7.483. [DOI] [PubMed] [Google Scholar]
  13. Fischer P. B., Collin M., Karlsson G. B., James W., Butters T. D., Davis S. J., Gordon S., Dwek R. A., Platt F. M. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J Virol. 1995 Sep;69(9):5791–5797. doi: 10.1128/jvi.69.9.5791-5797.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fischer P. B., Karlsson G. B., Butters T. D., Dwek R. A., Platt F. M. N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J Virol. 1996 Oct;70(10):7143–7152. doi: 10.1128/jvi.70.10.7143-7152.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fischl M. A., Resnick L., Coombs R., Kremer A. B., Pottage J. C., Jr, Fass R. J., Fife K. H., Powderly W. G., Collier A. C., Aspinall R. L. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr. 1994 Feb;7(2):139–147. [PubMed] [Google Scholar]
  16. Fleet G. W., Karpas A., Dwek R. A., Fellows L. E., Tyms A. S., Petursson S., Namgoong S. K., Ramsden N. G., Smith P. W., Son J. C. Inhibition of HIV replication by amino-sugar derivatives. FEBS Lett. 1988 Sep 12;237(1-2):128–132. doi: 10.1016/0014-5793(88)80185-6. [DOI] [PubMed] [Google Scholar]
  17. Grabowski G. A., Barton N. W., Pastores G., Dambrosia J. M., Banerjee T. K., McKee M. A., Parker C., Schiffmann R., Hill S. C., Brady R. O. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995 Jan 1;122(1):33–39. doi: 10.7326/0003-4819-122-1-199501010-00005. [DOI] [PubMed] [Google Scholar]
  18. Hollak C. E., Aerts J. M., Goudsmit R., Phoa S. S., Ek M., van Weely S., von dem Borne A. E., van Oers M. H. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet. 1995 Jun 10;345(8963):1474–1478. doi: 10.1016/s0140-6736(95)91037-9. [DOI] [PubMed] [Google Scholar]
  19. Hollak C. E., van Weely S., van Oers M. H., Aerts J. M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994 Mar;93(3):1288–1292. doi: 10.1172/JCI117084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jeyakumar M., Butters T. D., Cortina-Borja M., Hunnam V., Proia R. L., Perry V. H., Dwek R. A., Platt F. M. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6388–6393. doi: 10.1073/pnas.96.11.6388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Karlsson G. B., Butters T. D., Dwek R. A., Platt F. M. Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120. J Biol Chem. 1993 Jan 5;268(1):570–576. [PubMed] [Google Scholar]
  22. Lachmann R. H., Platt F. M. Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin Investig Drugs. 2001 Mar;10(3):455–466. doi: 10.1517/13543784.10.3.455. [DOI] [PubMed] [Google Scholar]
  23. Pastores G. M., Sibille A. R., Grabowski G. A. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood. 1993 Jul 15;82(2):408–416. [PubMed] [Google Scholar]
  24. Persidis A. Proteomics. Nat Biotechnol. 1998 Apr;16(4):393–394. doi: 10.1038/nbt0498-393. [DOI] [PubMed] [Google Scholar]
  25. Petrescu S. M., Branza-Nichita N., Negroiu G., Petrescu A. J., Dwek R. A. Tyrosinase and glycoprotein folding: roles of chaperones that recognize glycans. Biochemistry. 2000 May 9;39(18):5229–5237. doi: 10.1021/bi000107z. [DOI] [PubMed] [Google Scholar]
  26. Platt F. M., Butters T. D. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem Pharmacol. 1998 Aug 15;56(4):421–430. doi: 10.1016/s0006-2952(98)00115-4. [DOI] [PubMed] [Google Scholar]
  27. Platt F. M., Karlsson G. B., Jacob G. S. Modulation of cell-surface transferrin receptor by the imino sugar N-butyldeoxynojirimycin. Eur J Biochem. 1992 Aug 15;208(1):187–193. doi: 10.1111/j.1432-1033.1992.tb17173.x. [DOI] [PubMed] [Google Scholar]
  28. Platt F. M., Neises G. R., Dwek R. A., Butters T. D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994 Mar 18;269(11):8362–8365. [PubMed] [Google Scholar]
  29. Platt F. M., Neises G. R., Reinkensmeier G., Townsend M. J., Perry V. H., Proia R. L., Winchester B., Dwek R. A., Butters T. D. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997 Apr 18;276(5311):428–431. doi: 10.1126/science.276.5311.428. [DOI] [PubMed] [Google Scholar]
  30. Platt Frances M., Jeyakumar Mylvaganam, Andersson Ulrika, Heare Tanya, Dwek Raymond A., Butters Terry D. Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):947–954. doi: 10.1098/rstb.2003.1279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Suzuki K., Proia R. L., Suzuki K. Mouse models of human lysosomal diseases. Brain Pathol. 1998 Jan;8(1):195–215. doi: 10.1111/j.1750-3639.1998.tb00145.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Van Weely S., Van Leeuwen M. B., Jansen I. D., De Bruijn M. A., Brouwer-Kelder E. M., Schram A. W., Sa Miranda M. C., Barranger J. A., Petersen E. M., Goldblatt J. Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta. 1991 Jun 5;1096(4):301–311. doi: 10.1016/0925-4439(91)90066-i. [DOI] [PubMed] [Google Scholar]
  33. Young E., Chatterton C., Vellodi A., Winchester B. Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. J Inherit Metab Dis. 1997 Aug;20(4):595–602. doi: 10.1023/a:1005367328003. [DOI] [PubMed] [Google Scholar]
  34. Zimran A., Elstein D., Kannai R., Zevin S., Hadas-Halpern I., Levy-Lahad E., Cohen Y., Horowitz M., Abrahamov A. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med. 1994 Jul;97(1):3–13. doi: 10.1016/0002-9343(94)90042-6. [DOI] [PubMed] [Google Scholar]
  35. Zimran A., Elstein D., Levy-Lahad E., Zevin S., Hadas-Halpern I., Bar-Ziv Y., Foldes J., Schwartz A. J., Abrahamov A. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet. 1995 Jun 10;345(8963):1479–1480. doi: 10.1016/s0140-6736(95)91038-7. [DOI] [PubMed] [Google Scholar]

Articles from Philosophical Transactions of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

RESOURCES